ImmunityBio Inc. (NASDAQ:IBRX) saw an 11th consecutive day of gains, hitting a new 52-week high on Friday. The stock surged to $5.58 before closing at $5.52, up 39.75%. Positive catalysts included a 700% sales increase, entry into a new international market, and promising clinical trial results for a rare blood cancer treatment.

ImmunityBio Inc. (NASDAQ:IBRX) reported that its CD19 CAR-NK treatment, combined with rituximab, controlled the disease in four patients, with two achieving complete remission at 7 and 15 months. Tumors disappeared after two cycles, showing potential for long-term disease control without continuous therapy.

ImmunityBio Inc. (NASDAQ:IBRX) announced a 700% revenue increase from Anktiva, totaling $113 million for 2025, driven by strong demand. The company also received FDA approval to sell and market Anktiva in Saudi Arabia, expanding its operations internationally. Investors should consider AI stocks with higher return potential and lower downside risk.

For more insights on potential investment opportunities, check out our free report on the best short-term AI stock. Visit Insider Monkey for more news and analysis.

Read more at Yahoo Finance: ImmunityBio (IBRX) Rallies on 11th Day, Hits 52-Week High on Strong Clinical Trial Results